Jinhan Kim, Standigm CEO is supposed to attend the BIO International Convention 2019.

Standigm, a company using artificial intelligence (AI) technology for drug discovery and development, announced it has raised 11.5 million dolloar in a Series B funding round led by Mirae Asset Venture Investment and Mirae Asset Capital. Standigm will use the funds to scale the AI technology platforms and advance its drug discovery pipelines toward license-out. The new round brings Standigm’s total financing to $15 million.

Standigm is developing drugs for NASH, Parkinson, autism.

Hee Jung Koo and Daehee Han will attend the BIO Asia International Conference 2019.

Jinhan Kim, Standigm CEO, and Heejung Koo will attend the BIO International Convention 2018.